Biophytis S.A. (ALBPS.PA)

EUR 0.33

(0.92%)

Revenue Summary of Biophytis S.A.

  • Biophytis S.A.'s latest annual revenue in 2023 was - EUR , down 0.0% from previous year.
  • Biophytis S.A.'s latest quarterly revenue in 2024 Q1 was - EUR , down 0.0% from previous quarter.
  • Biophytis S.A. reported a annual revenue of - EUR in annual revenue 2022, down 0.0% from previous year.
  • Biophytis S.A. reported a annual revenue of - EUR in annual revenue 2021, down 0.0% from previous year.
  • Biophytis S.A. reported a quarterly revenue of - EUR for 2024 Q1, down 0.0% from previous quarter.
  • Biophytis S.A. reported a quarterly revenue of - EUR for 2023 Q2, down 0.0% from previous quarter.

Annual Revenue Chart of Biophytis S.A. (2023 - 2013)

Historical Annual Revenue of Biophytis S.A. (2023 - 2013)

Year Revenue Revenue Growth
2023 - EUR 0.0%
2022 - EUR 0.0%
2021 - EUR 0.0%
2020 - EUR 0.0%
2019 - EUR 0.0%
2018 - EUR 0.0%
2017 - EUR 0.0%
2016 - EUR 0.0%
2015 - EUR 0.0%
2014 - EUR 0.0%
2013 - EUR 0.0%

Peer Revenue Comparison of Biophytis S.A.

Name Revenue Revenue Difference
ABIONYX Pharma SA 4.64 Million EUR 100.0%
ABIVAX Société Anonyme 4.62 Million EUR 100.0%
Adocia SA 2.15 Million EUR 100.0%
Aelis Farma SA 9.05 Million EUR 100.0%
Advicenne S.A. 3.15 Million EUR 100.0%
genOway Société anonyme 20.04 Million EUR 100.0%
IntegraGen SA 12.53 Million EUR 100.0%
Medesis Pharma S.A. 300.03 Thousand EUR 100.0%
Neovacs S.A. 533.41 Thousand EUR 100.0%
NFL Biosciences SA - EUR NaN%
Plant Advanced Technologies SA 1.68 Million EUR 100.0%
Quantum Genomics Société Anonyme 19.79 Thousand EUR 100.0%
Sensorion SA 4.74 Million EUR 100.0%
Theranexus Société Anonyme 296.33 Thousand EUR 100.0%
TME Pharma N.V. 17 Thousand EUR 100.0%
Valbiotis SA 4.73 Million EUR 100.0%
TheraVet SA 1.07 Million EUR 100.0%
Valerio Therapeutics Société anonyme 1.8 Million EUR 100.0%
argenx SE 1.13 Billion EUR 100.0%
BioSenic S.A. 543 Thousand EUR 100.0%
Celyad Oncology SA 102 Thousand EUR 100.0%
DBV Technologies S.A. - EUR NaN%
Galapagos NV 239.72 Million EUR 100.0%
Genfit S.A. 28.56 Million EUR 100.0%
GeNeuro SA - EUR NaN%
Hyloris Pharmaceuticals SA 2.08 Million EUR 100.0%
Innate Pharma S.A. 51.9 Million EUR 100.0%
Inventiva S.A. 17.47 Million EUR 100.0%
MaaT Pharma SA 2.22 Million EUR 100.0%
MedinCell S.A. 9.16 Million EUR 100.0%
Nanobiotix S.A. 30.05 Million EUR 100.0%
Onward Medical N.V. 532 Thousand EUR 100.0%
Oryzon Genomics S.A. 14.19 Million EUR 100.0%
OSE Immunotherapeutics SA 2.22 Million EUR 100.0%
Oxurion NV 263 Thousand EUR 100.0%
Pharming Group N.V. 245.31 Million EUR 100.0%
Poxel S.A. 1.98 Million EUR 100.0%
GenSight Biologics S.A. 1.26 Million EUR 100.0%
Transgene SA 1.18 Million EUR 100.0%
Financière de Tubize SA - EUR NaN%
UCB SA 5.25 Billion EUR 100.0%
Valneva SE 153.71 Million EUR 100.0%
Vivoryon Therapeutics N.V. -3.62 Million EUR 100.0%